Summary
|
|
---|---|
EudraCT Number: | 2011-003604-21 |
Sponsor's Protocol Code Number: | KT-IBA |
National Competent Authority: | Austria - BASG |
Clinical Trial Type: | EEA CTA |
Trial Status: | Completed |
Date on which this record was first entered in the EudraCT database: | 2011-09-19 |
Trial results | View results |
Expand All
Collapse All
A. Protocol Information
|
|||
---|---|---|---|
A.1 | Member State Concerned | Austria - BASG | |
A.2 | EudraCT number | 2011-003604-21 | |
A.3 | Full title of the trial |
|
|
A.3.1 | Title of the trial for lay people, in easily understood, i.e. non-technical, language |
|
|
A.3.2 | Name or abbreviated title of the trial where available |
|
|
A.4.1 | Sponsor's protocol code number | KT-IBA | |
A.7 | Trial is part of a Paediatric Investigation Plan | No | |
A.8 | EMA Decision number of Paediatric Investigation Plan |
B. Sponsor Information
|
||
---|---|---|
B.Sponsor: 1 | ||
B.1.1 | Name of Sponsor | Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck |
B.1.3.4 | Country | Austria |
B.3.1 and B.3.2 | Status of the sponsor | Non-Commercial |
B.4 Source(s) of Monetary or Material Support for the clinical trial: | ||
B.4.1 | Name of organisation providing support | Verein für nephrologische Forschung |
B.4.2 | Country | Austria |
B.5 Contact point designated by the sponsor for further information on the trial | ||
B.5.1 | Name of organisation | Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck |
B.5.2 | Functional name of contact point | Gert Mayer |
B.5.3 | Address: | |
B.5.3.1 | Street Address | Anichstr. 35 |
B.5.3.2 | Town/ city | Innsbruck |
B.5.3.3 | Post code | 6020 |
B.5.3.4 | Country | Austria |
B.5.4 | Telephone number | +4351250425885 |
B.5.5 | Fax number | +4351250425857 |
B.5.6 | gert.mayer@i-med.ac.at |
D. IMP Identification
|
||
---|---|---|
D.IMP: 1 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Certican |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Novartis Pharma GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Austria |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | Certican |
D.3.4 | Pharmaceutical form | Tablet |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 2 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Rapamune |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Wyeth Europe Ltd |
D.2.1.2 | Country which granted the Marketing Authorisation | Austria |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | Rapamune |
D.3.4 | Pharmaceutical form | Coated tablet |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 3 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Sandimmun Neoral |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Novartis Pharma GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Austria |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | Sandimmun |
D.3.4 | Pharmaceutical form | Capsule, soft |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 4 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Prograf |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Astellas Pharma GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Austria |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | Prograf |
D.3.4 | Pharmaceutical form | Capsule, hard |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.8 Information on Placebo
|
---|
E. General Information on the Trial
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E.1 Medical condition or disease under investigation | |||||||||||||||||
E.1.1 | Medical condition(s) being investigated |
|
|||||||||||||||
E.1.1.1 | Medical condition in easily understood language |
|
|||||||||||||||
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] | |||||||||||||||
MedDRA Classification | |||||||||||||||||
E.1.2 Medical condition or disease under investigation | |||||||||||||||||
|
|||||||||||||||||
E.1.3 | Condition being studied is a rare disease | No | |||||||||||||||
E.2 Objective of the trial | |||||||||||||||||
E.2.1 | Main objective of the trial | ||||||||||||||||
E.2.2 | Secondary objectives of the trial | ||||||||||||||||
E.2.3 | Trial contains a sub-study | No | |||||||||||||||
E.3 | Principal inclusion criteria |
|
|||||||||||||||
E.4 | Principal exclusion criteria |
|
|||||||||||||||
E.5 End points | |||||||||||||||||
E.5.1 | Primary end point(s) |
|
|||||||||||||||
E.6 and E.7 Scope of the trial | |||||||||||||||||
E.6 | Scope of the trial | ||||||||||||||||
E.6.1 | Diagnosis | No | |||||||||||||||
E.6.2 | Prophylaxis | No | |||||||||||||||
E.6.3 | Therapy | No | |||||||||||||||
E.6.4 | Safety | No | |||||||||||||||
E.6.5 | Efficacy | No | |||||||||||||||
E.6.6 | Pharmacokinetic | No | |||||||||||||||
E.6.7 | Pharmacodynamic | No | |||||||||||||||
E.6.8 | Bioequivalence | No | |||||||||||||||
E.6.9 | Dose response | No | |||||||||||||||
E.6.10 | Pharmacogenetic | No | |||||||||||||||
E.6.11 | Pharmacogenomic | No | |||||||||||||||
E.6.12 | Pharmacoeconomic | No | |||||||||||||||
E.6.13 | Others | Yes | |||||||||||||||
E.6.13.1 | Other scope of the trial description |
|
|||||||||||||||
E.7 | Trial type and phase | ||||||||||||||||
E.7.1 | Human pharmacology (Phase I) | No | |||||||||||||||
E.7.1.1 | First administration to humans | No | |||||||||||||||
E.7.1.2 | Bioequivalence study | No | |||||||||||||||
E.7.1.3 | Other | No | |||||||||||||||
E.7.1.3.1 | Other trial type description | ||||||||||||||||
E.7.2 | Therapeutic exploratory (Phase II) | No | |||||||||||||||
E.7.3 | Therapeutic confirmatory (Phase III) | No | |||||||||||||||
E.7.4 | Therapeutic use (Phase IV) | Yes | |||||||||||||||
E.8 Design of the trial | |||||||||||||||||
E.8.1 | Controlled | No | |||||||||||||||
E.8.1.1 | Randomised | No | |||||||||||||||
E.8.1.2 | Open | Yes | |||||||||||||||
E.8.1.3 | Single blind | No | |||||||||||||||
E.8.1.4 | Double blind | No | |||||||||||||||
E.8.1.5 | Parallel group | No | |||||||||||||||
E.8.1.6 | Cross over | No | |||||||||||||||
E.8.1.7 | Other | No | |||||||||||||||
E.8.2 | Comparator of controlled trial | ||||||||||||||||
E.8.2.1 | Other medicinal product(s) | No | |||||||||||||||
E.8.2.2 | Placebo | No | |||||||||||||||
E.8.2.3 | Other | No | |||||||||||||||
E.8.3 | The trial involves single site in the Member State concerned | Yes | |||||||||||||||
E.8.4 | The trial involves multiple sites in the Member State concerned | No | |||||||||||||||
E.8.5 | The trial involves multiple Member States | No | |||||||||||||||
E.8.5.1 | Number of sites anticipated in the EEA | 1 | |||||||||||||||
E.8.6 Trial involving sites outside the EEA | |||||||||||||||||
E.8.6.1 | Trial being conducted both within and outside the EEA | No | |||||||||||||||
E.8.6.2 | Trial being conducted completely outside of the EEA | No | |||||||||||||||
E.8.7 | Trial has a data monitoring committee | No | |||||||||||||||
E.8.8 | Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial |
|
|||||||||||||||
E.8.9 Initial estimate of the duration of the trial | |||||||||||||||||
E.8.9.1 | In the Member State concerned years | 2 | |||||||||||||||
E.8.9.1 | In the Member State concerned months | ||||||||||||||||
E.8.9.1 | In the Member State concerned days | ||||||||||||||||
E.8.9.2 | In all countries concerned by the trial years | 2 |
F. Population of Trial Subjects
|
||
---|---|---|
F.1 Age Range | ||
F.1.1 | Trial has subjects under 18 | No |
F.1.1.1 | In Utero | No |
F.1.1.2 | Preterm newborn infants (up to gestational age < 37 weeks) | No |
F.1.1.3 | Newborns (0-27 days) | No |
F.1.1.4 | Infants and toddlers (28 days-23 months) | No |
F.1.1.5 | Children (2-11years) | No |
F.1.1.6 | Adolescents (12-17 years) | No |
F.1.2 | Adults (18-64 years) | Yes |
F.1.2.1 | Number of subjects for this age range: | 150 |
F.1.3 | Elderly (>=65 years) | Yes |
F.1.3.1 | Number of subjects for this age range: | 50 |
F.2 Gender | ||
F.2.1 | Female | Yes |
F.2.2 | Male | Yes |
F.3 Group of trial subjects | ||
F.3.1 | Healthy volunteers | Yes |
F.3.2 | Patients | Yes |
F.3.3 | Specific vulnerable populations | Yes |
F.3.3.1 | Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2011-09-19. | Yes |
F.3.3.2 | Women of child-bearing potential using contraception | Yes |
F.3.3.3 | Pregnant women | No |
F.3.3.4 | Nursing women | Yes |
F.3.3.5 | Emergency situation | No |
F.3.3.6 | Subjects incapable of giving consent personally | No |
F.3.3.7 | Others | No |
F.4 Planned number of subjects to be included | ||
F.4.1 | In the member state | 200 |
G. Investigator Networks to be involved in the Trial
|
---|
N. Review by the Competent Authority or Ethics Committee in the country concerned
|
||
---|---|---|
N. | Competent Authority Decision | Authorised |
N. | Date of Competent Authority Decision | 2011-10-20 |
N. | Ethics Committee Opinion of the trial application | Favourable |
N. | Ethics Committee Opinion: Reason(s) for unfavourable opinion |
|
N. | Date of Ethics Committee Opinion | 2011-10-24 |
P. End of Trial
|
||
---|---|---|
P. | End of Trial Status | Completed |
P. | Date of the global end of the trial | 2011-09-04 |